PL3634417T3 - Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem - Google Patents
Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworemInfo
- Publication number
- PL3634417T3 PL3634417T3 PL18803171.0T PL18803171T PL3634417T3 PL 3634417 T3 PL3634417 T3 PL 3634417T3 PL 18803171 T PL18803171 T PL 18803171T PL 3634417 T3 PL3634417 T3 PL 3634417T3
- Authority
- PL
- Poland
- Prior art keywords
- quinazoline
- cancer
- treatment
- related disorders
- pyrazole derivatives
- Prior art date
Links
- ARMQQOXIHQRINP-UHFFFAOYSA-N 1H-pyrazole quinazoline Chemical class C=1C=NNC=1.N1=CN=CC2=CC=CC=C21 ARMQQOXIHQRINP-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507540P | 2017-05-17 | 2017-05-17 | |
| PCT/US2018/032868 WO2018213377A1 (en) | 2017-05-17 | 2018-05-16 | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3634417T3 true PL3634417T3 (pl) | 2023-09-25 |
Family
ID=64274816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18803171.0T PL3634417T3 (pl) | 2017-05-17 | 2018-05-16 | Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11220492B2 (enExample) |
| EP (1) | EP3634417B1 (enExample) |
| JP (1) | JP7189155B2 (enExample) |
| CN (1) | CN110636846B (enExample) |
| ES (1) | ES2951809T3 (enExample) |
| PL (1) | PL3634417T3 (enExample) |
| WO (1) | WO2018213377A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR117844A1 (es) * | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
| AU2020239048B2 (en) | 2019-03-12 | 2025-10-16 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| JP7743309B2 (ja) | 2019-03-29 | 2025-09-24 | アーカス バイオサイエンシズ インコーポレイティド | 同定されたアデノシンフィンガープリントを利用したがんの処置 |
| WO2021188769A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
| AU2021292195A1 (en) | 2020-06-17 | 2023-01-05 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
| CN112326961B (zh) * | 2020-10-30 | 2021-08-06 | 福州迈新生物技术开发有限公司 | 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备 |
| CN112691107B (zh) * | 2021-02-03 | 2022-09-02 | 北京斯利安药业有限公司 | 一种药物组合物及其应用 |
| WO2022166796A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
| CN113642386B (zh) * | 2021-07-02 | 2024-06-21 | 广州金域医学检验中心有限公司 | 基于深度学习评价鼻咽癌治疗效果的方法、装置、设备和介质 |
| AU2022376961A1 (en) | 2021-10-29 | 2024-05-16 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| US20240124490A1 (en) | 2022-07-15 | 2024-04-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| EP4558501A1 (en) | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| EP4604920A1 (en) | 2022-10-20 | 2025-08-27 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| US20240425497A1 (en) | 2023-05-05 | 2024-12-26 | Arcus Biosciences, Inc. | Cbl-b Inhibitors and Methods of Use Thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN119139469A (zh) * | 2023-06-16 | 2024-12-17 | 武汉大学 | 腺苷受体抑制剂在制备用于治疗高脂血症与心脑血管疾病的药物中的应用 |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| WO2025076299A1 (en) | 2023-10-06 | 2025-04-10 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025096979A1 (en) | 2023-11-02 | 2025-05-08 | Arcus Biosciences, Inc. | Thiazole compounds as kit inhibitors and methods of use thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE205202T1 (de) | 1992-03-13 | 2001-09-15 | Merck Sharp & Dohme | Imidazol-, triazol- und tetrazolderivate |
| GB9207396D0 (en) | 1992-04-03 | 1992-05-13 | Merck Sharp & Dohme | Therapeutic agents |
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| JP4109123B2 (ja) | 2001-05-09 | 2008-07-02 | セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド | ペプチドデホルミラーゼ活性化プロドラッグ |
| US6642390B2 (en) | 2001-07-11 | 2003-11-04 | Lexicon Pharmaceuticals, Inc. | One step synthesis of 1,2,3-triazole carboxylic acids |
| JP4299139B2 (ja) | 2001-12-18 | 2009-07-22 | メルク エンド カムパニー インコーポレーテッド | 代謝型グルタミン酸受容体−５のヘテロアリール置換トリアゾールモジュレータ |
| WO2003090751A1 (en) | 2002-04-26 | 2003-11-06 | Pfizer Products Inc. | Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors |
| US7354938B2 (en) * | 2004-03-23 | 2008-04-08 | Amgen Inc. | Pyrazole compounds and uses related thereto |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| ZA200707482B (en) | 2005-02-04 | 2008-12-31 | Senomyx Inc | Compounds comprising linked heteroaryl moieties and their use as novel umami flavour modifiers, tastants and taste enhancers for comestible compositions |
| WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| NZ571324A (en) * | 2006-03-17 | 2011-07-29 | Gilead Palo Alto Inc | Method of preventing and treating hepatic disease using A2B adenoise receptor antagonists |
| EP2041115A4 (en) | 2006-07-04 | 2010-07-07 | Astrazeneca Ab | NEW PYRIDINE ANALOG |
| US7994321B2 (en) | 2006-08-08 | 2011-08-09 | Hoffmann-La Roche Inc. | Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| PE20091953A1 (es) | 2008-05-08 | 2010-01-09 | Du Pont | Azoles sustituidos como fungicidas |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| BRPI0917394A2 (pt) | 2008-08-18 | 2019-09-24 | Univ Yale | moduladores de mif |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| CN102388037B (zh) * | 2009-02-10 | 2014-12-03 | 詹森药业有限公司 | 作为脯氨酰羟化酶抑制剂的喹唑啉酮 |
| WO2010108187A2 (en) | 2009-03-20 | 2010-09-23 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| WO2010144780A1 (en) | 2009-06-12 | 2010-12-16 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
| WO2011005806A1 (en) | 2009-07-08 | 2011-01-13 | Isp Investments Inc. | 4- and 5 substituted 1,2,3- triazole moieties with at least one remote polymerizable moiety and polymers thereof |
| CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
| WO2011050284A1 (en) * | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Pyrazolylpyridine antiviral agents |
| PT2949670T (pt) | 2009-12-10 | 2019-05-20 | Hoffmann La Roche | Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização |
| US20130030359A1 (en) | 2010-01-22 | 2013-01-31 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ705128A (en) | 2010-03-04 | 2015-04-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011107553A1 (en) | 2010-03-05 | 2011-09-09 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| CN110269856A (zh) | 2010-03-30 | 2019-09-24 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| CN107011438B (zh) | 2010-05-04 | 2020-11-20 | 戊瑞治疗有限公司 | 结合csf1r的抗体 |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| US8748435B2 (en) * | 2011-04-01 | 2014-06-10 | Novartis Ag | Pyrazolo pyrimidine derivatives |
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013085890A1 (en) | 2011-12-06 | 2013-06-13 | Glaxo Group Limited | Therapeutic methods |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| CA2861122A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
| PL2820006T3 (pl) * | 2012-02-29 | 2018-02-28 | Chemocentryx, Inc. | Benzosulfonamidy pirazolo-1-ilowe jako antagoniści CCR9 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| DE102012102162A1 (de) | 2012-03-14 | 2013-09-19 | Westfälische Wilhelms-Universität Münster Körperschaft des öffentlichen Rechts | Ionenleitende polymere Verbindung für elektrochemische Zellen |
| AU2012374617B2 (en) | 2012-05-11 | 2015-09-17 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US9365527B2 (en) | 2013-03-14 | 2016-06-14 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| CN105873577B (zh) | 2013-08-30 | 2019-06-18 | 西奈山伊坎医学院 | 环插烯酰胺作为溴结构域抑制剂 |
| EP2903044A1 (de) | 2014-02-04 | 2015-08-05 | cynora GmbH | Organische Moleküle zur Verwendung in optoelektronischen Bauelementen |
| US10052332B2 (en) | 2014-04-29 | 2018-08-21 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| US20160251341A1 (en) | 2015-02-27 | 2016-09-01 | Verseon Corporation | Substituted triazole compounds as serine protease inhibitors |
| EP3347008B1 (en) | 2015-09-11 | 2022-03-09 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| MX389798B (es) | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| US11045472B2 (en) | 2017-05-05 | 2021-06-29 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
-
2018
- 2018-05-16 WO PCT/US2018/032868 patent/WO2018213377A1/en not_active Ceased
- 2018-05-16 ES ES18803171T patent/ES2951809T3/es active Active
- 2018-05-16 EP EP18803171.0A patent/EP3634417B1/en active Active
- 2018-05-16 PL PL18803171.0T patent/PL3634417T3/pl unknown
- 2018-05-16 CN CN201880032987.1A patent/CN110636846B/zh active Active
- 2018-05-16 US US16/614,063 patent/US11220492B2/en active Active
- 2018-05-16 JP JP2019563142A patent/JP7189155B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3634417A4 (en) | 2021-01-13 |
| WO2018213377A1 (en) | 2018-11-22 |
| US20210214346A1 (en) | 2021-07-15 |
| CN110636846B (zh) | 2023-05-16 |
| US11220492B2 (en) | 2022-01-11 |
| CN110636846A (zh) | 2019-12-31 |
| EP3634417C0 (en) | 2023-07-12 |
| EP3634417B1 (en) | 2023-07-12 |
| EP3634417A1 (en) | 2020-04-15 |
| JP2020519664A (ja) | 2020-07-02 |
| JP7189155B2 (ja) | 2022-12-13 |
| ES2951809T3 (es) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| PL3618829T3 (pl) | Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem | |
| PL3634417T3 (pl) | Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| IL256224B (en) | Combined therapy for cancer treatment | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| IL258521A (en) | Combination of treatments for cancer treatment | |
| IL259996A (en) | Combinations for cancer treatment | |
| IL267818A (en) | Methods for treating neurological disorders | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| IL258032A (en) | Compounds and preparations for the treatment of ocular disorders | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| IL259674B (en) | Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases | |
| IL273835A (en) | Combined product for cancer treatment | |
| EP3371154A4 (en) | HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| EP3507277B8 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| HK40101362A (zh) | 用於治疗癌症相关疾病的唑嘧啶 | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer | |
| HK1260601A1 (en) | Heterocycle derivatives and their use for the treatment of cns disorders | |
| GB201602784D0 (en) | New treatment of CFTR-related disorders |